Want to see TNXP full AI Analyst Report?
TNXP Stock Chart & Stats
$13.66
-$0.74(-6.97%)
At close: 4:00 PM EDT
$13.66
-$0.74(-6.97%)
Day’s Range― - ―
52-Week Range$9.40 - $31.55
Previous CloseN/A
Volume715.38K
Average Volume (3M)485.86K
Market Cap
$229.31M
Enterprise Value$37.31
Total Cash (Recent Filing)$176.23M
Total Debt (Recent Filing)$1.27M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 09, 2026EPS Estimate
-2.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.24
Shares Outstanding17,151,024
10 Day Avg. Volume515,648
30 Day Avg. Volume485,863
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.54
Price to Sales (P/S)10.14
P/FCF Ratio-1.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.00Price Target Upside178.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.72
Revenue Forecast (FY)$56.04M
Bulls Say, Bears Say
Bulls Say
TONMYA Commercial Traction And Payer ExpansionRapid sales, prescription and refill growth indicate early product acceptance, while expanding commercial and Medicare coverage broadens the reimbursed patient pool. Together, these factors can support a more durable revenue base as access converts into prescription volume.
Regulatory And Clinical Pipeline ProgressRegulatory alignment reduces design uncertainty and enables preparation for a large Phase 2 study, while TNX-102 SL has also entered randomized development. Progress across multiple programs preserves opportunities for label expansion and future portfolio value.
Low Financial LeverageMinimal debt reduces interest, refinancing and near-term solvency pressure compared with a highly leveraged development company. The sizable equity base provides some flexibility to fund operations and clinical programs, although continued losses can erode that buffer.
Bears Say
Persistent Losses And Weak Operating LeverageRevenue growth has not yet produced sustainable profitability because the cost structure remains far above the current revenue base. Unless commercialization scales materially or expenses moderate, ongoing losses will continue to consume capital and limit self-funded growth.
Heavy Cash Burn And Near-term Financing DependenceDeeply negative cash generation means Tonix relies on external financing rather than internally generated funds. The stated runway and dependence on subsequent equity proceeds create dilution and execution risk if commercial uptake, capital access or financing conditions disappoint.
Clinical Execution And Leadership Continuity RiskA senior medical leadership transition adds continuity and oversight risk during active clinical development. Separately, TNX-4800’s event-driven design may delay enrollment and readouts, extending spending and postponing evidence needed for regulatory and commercial decisions.
Tonix Pharma News
TNXP FAQ
What was Tonix Pharma’s price range in the past 12 months?
Tonix Pharma lowest stock price was $9.40 and its highest was $31.55 in the past 12 months.
What is Tonix Pharma’s market cap?
Tonix Pharma’s market cap is $229.31M.
When is Tonix Pharma’s upcoming earnings report date?
Tonix Pharma’s upcoming earnings report date is Nov 09, 2026 which is in 65 days.
How were Tonix Pharma’s earnings last quarter?
Tonix Pharma released its earnings results on Aug 10, 2026. The company reported -$2.44 earnings per share for the quarter, beating the consensus estimate of -$2.642 by $0.202.
Is Tonix Pharma overvalued?
According to Wall Street analysts Tonix Pharma’s price is currently Undervalued.
Does Tonix Pharma pay dividends?
Tonix Pharma does not currently pay dividends.
What is Tonix Pharma’s EPS estimate?
Tonix Pharma’s EPS estimate is -2.45.
How many shares outstanding does Tonix Pharma have?
Tonix Pharma has 17,151,024 shares outstanding.
What happened to Tonix Pharma’s price movement after its last earnings report?
Tonix Pharma reported an EPS of -$2.44 in its last earnings report, beating expectations of -$2.642. Following the earnings report the stock price went up 4.655%.
Which hedge fund is a major shareholder of Tonix Pharma?
Currently, no hedge funds are holding shares in TNXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tonix Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (178.18% Upside)
$38.00 (178.18% Upside)
Blogger Sentiment
Bullish
TNXP Sentiment 75%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth $172.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
TNXP Company Deck
TNXP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial momentum for TONMYA with strong near-term sales growth, improving prescription/refill metrics, expanding payer coverage, and concrete clinical progress on two mid-stage programs (TNX-102 SL for MDD and TNX-4800 for Lyme prevention). These operational positives are tempered by materially higher R&D and SG&A expenses, a limited cash runway into early Q2 2027 (requiring subsequent equity proceeds), ongoing gross-to-net and access variability, and event-driven risk for the TNX-4800 study that could delay readouts. Overall, the company demonstrates strong product and pipeline traction but faces near-term financial and trial-enrollment risks that warrant monitoring.View all TNXP earnings summariesTNXP Stock 12 Month Forecast
Average Price Target
$38.00
▲(178.18% Upside)
Technical Analysis
Ownership Overview
0.24% Insiders
6.03% Mutual Funds
8.50% Other Institutional Investors
75.14% Public Companies and
Individual Investors